Literature DB >> 28624173

High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.

Hanan Sayed M Abozaid1, Hala M K Imam2, Marwa Mahmoud Abdelaziz3, Dina H El-Hammady4, Nihal A Fathi3, Daniel E Furst5.   

Abstract

OBJECTIVES: To study esophageal high resolution manometry (HRM) in systemic sclerosis (SSc) patients and the correlation of findings to The University of California, Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 (UCLA SCTC_GIT 2.0).
METHODS: Forty SSc patients were administered to the UCLA SCTC GIT 2.0. Patients underwent HRM study (Solar GI MMS). HRM data were compared with 15 healthy volunteers.
RESULTS: Forty patients with mean age 46 ± 7 years and disease duration 9.3 ± 7 years reported upper (85.7%), lower GI symptoms (75%), while 5% reported no symptoms. Mean ± SD scores of UCLA SCTC_GIT 2.0 items were as follows: reflux 1.2 ± 0.8, distention 1.6 ± 1.2, fecal soiling 0.3 ± 0.9, diarrhea 0.8 ± 1, social 1 ± 1, emotional 1 ± 1.1, constipation 0.5 ± 0.9, and total GIT score 0.9 ± 0.6. Lower esophageal sphincter (LES) pressure and distal esophageal amplitude were significantly lower in SSc patients than controls. Main manometric findings were decreased LES resting pressure (40%) and aperistalsis (40%). Regression analyses showed distal esophageal amplitude and LES resting pressure negatively correlated with reflux score (r = -0.64; p = 0.001 and r = -0.46; p = 0.019, respectively), and total GIT score (r = -0.54; p = 0.007 and r = -0.42; p = 0.03, respectively). LES resting pressure had negative correlations with diarrhea score (r = -0.062; p = 0.002).
CONCLUSIONS: Decreased distal esophageal amplitude encountered as hypoperistalsis or even aperistalsis was associated with increased reflux and GIT scores (negatively correlated) UCLA SCTC_GIT 2.0 questionnaires. The GIT2.0 is easy to use and can serve as an indicator that further testing of the GI tract, including the esophagus, is indicated.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Esophageal high resolution manometry; Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0; Systemic sclerosis; The University of California

Mesh:

Year:  2017        PMID: 28624173     DOI: 10.1016/j.semarthrit.2017.05.005

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

Review 1.  Rheumatology in Egypt: back to the future.

Authors:  Tamer A Gheita; Nahla N Eesa
Journal:  Rheumatol Int       Date:  2018-11-07       Impact factor: 2.631

Review 2.  The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review.

Authors:  Wouter Schutyser; Ludovic Cruyt; Jean-Baptiste Vulsteke; Jan L Lenaerts; Ellen De Langhe
Journal:  Clin Rheumatol       Date:  2019-11-11       Impact factor: 2.980

3.  Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Authors:  Serena Vettori; Salvatore Tolone; Domenico Capocotta; Rossella Chieffo; Veronica Giacco; Gabriele Valentini; Ludovico Docimo
Journal:  Clin Rheumatol       Date:  2018-02-13       Impact factor: 2.980

Review 4.  GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis.

Authors:  Marie-Pier Tétreault; Peter Kahrilas
Journal:  Curr Rheumatol Rep       Date:  2019-07-03       Impact factor: 4.592

5.  Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.

Authors:  Norina Zampatti; Alexandru Garaiman; Suzana Jordan; Rucsandra Dobrota; Mike Oliver Becker; Britta Maurer; Oliver Distler; Carina Mihai
Journal:  Arthritis Res Ther       Date:  2021-04-22       Impact factor: 5.156

Review 6.  Esophageal manifestation in patients with scleroderma.

Authors:  Theodoros A Voulgaris; Georgios P Karamanolis
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.